Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates

Mindset Pharma Inc.(CNSX: MSET)(OTCMKTS: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that, in addition to its potential lead new chemical entity (“NCE”) candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020. In preclinical studies, both compounds demonstrated strong efficacy and an improved safety profile in comparison to 5-MeO-DMT and parent compounds.

Our Family 4 compounds leverage Mindset’s conjugate amplification technology, which has enabled us to rapidly generate clinical candidates that improve upon first-generation psychedelic efficacy and safety. Using a platform approach to advance our differentiated compounds into the clinic, we aim to broaden patient access for mental health sufferers and provide solutions to address a range of patient needs.

James Lanthier, CEO of Mindset

“The preclinical results of MSP-4019 and MSP-4020 demonstrated strong efficacy through a mouse head twitch assay and an improved safety profile at a range of doses up to 30 mg/kg,” stated Joseph Araujo, Chief Scientific Officer of Mindset. “Our next generation compounds showed no signs of 5-HT syndrome, a serious potential health risk associated with first-generation drugs, 5-MeO-DMT and DMT. We will continue to validate our novel compounds through translational models as we select one or more lead drug candidates from our Family 4 NCEs to advance into the clinic.”

Mindset’s Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

To watch a video of Mindset’s CEO discussing the announcement in greater detail, please visit: https://youtu.be/hy-pQlUegP0.

To view the original press release in its entirety click here

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More